| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.10. | Zentalis to present azenosertib data at cancer therapeutics conference | 5 | Investing.com | ||
| 01.10. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 55 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.09. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 94 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.08. | Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary | 4 | GlobeNewswire (USA) | ||
| 26.08. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 06.08. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.07. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 126 | GlobeNewswire (Europe) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 18.06. | Aktionäre von Zentalis Pharmaceuticals wählen drei Direktoren bei Jahreshauptversammlung | 3 | Investing.com Deutsch | ||
| 18.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 84 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Zentalis Pharmaceuticals GAAP EPS of -$0.67 misses by $0.04 | 1 | Seeking Alpha | ||
| 14.05. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.05. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 153 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 28.04. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.04. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 153 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.03. | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | 165 | GlobeNewswire (Europe) | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part... ► Artikel lesen | |
| 03.03. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 143 | GlobeNewswire (Europe) | SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 03.02. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 159 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,616 | -0,30 % | PRESSESPIEGEL/Unternehmen: LEG, DEUTSCHE BAHN, FLINK, BIONTECH/CUREVAC, NEURAXPHARM | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
LEG - Der Chef des zweitgrößten deutschen Vermieters LEG, Lars von Lackum... ► Artikel lesen | |
| MODERNA | 22,675 | -2,05 % | Tesla- & IBM-Bilanzen enttäuschen - D-Wave, Moderna, Honeywell, T-Mobile US | Nach dem Rekordlauf vom Dienstag haben die Anleger an der Wall Street am Mittwoch Kasse gemacht. Der Dow Jones verlor zum Handelsschluss 0,71 Prozent. Besonders deutlich fiel die Korrektur im Technologiesektor... ► Artikel lesen | |
| VALNEVA | 4,110 | +0,49 % | Valneva-Aktie unter Druck - Anleger verlieren vorerst das Vertrauen in den Impfstoffhersteller! | ||
| NOVAVAX | 7,144 | -0,68 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,441 | -4,55 % | NurExone setzt neue Standards: Patente und Qualität als Fundament für den nächsten Schritt | ||
| CARDIFF ONCOLOGY | 1,922 | +0,73 % | Cardiff Oncology: Neue Impulse voraus? | Mit der Aktie von Cardiff Oncology haben Mitglieder von sharedealsPlus in der Vergangenheit mehrfach hervorragend verdient. Zuletzt konnten im Rahmen eines Daten-Run-up-Szenarios über 30% Kursgewinn... ► Artikel lesen | |
| IMMUNITYBIO | 2,078 | +1,22 % | ImmunityBio: Zwischen Hype und Hoffnung | Die Aktie von ImmunityBio hat in den vergangenen eineinhalb Jahren deutlich an Wert verloren, nachdem Finanzierungsbedarf zu einer erheblichen Verwässerung führte. Dennoch rückt das Unternehmen dank... ► Artikel lesen | |
| ALDEYRA | 4,457 | +0,04 % | Jefferies erhöht Kursziel für Aldeyra Therapeutics nach FDA-Annahme auf 7 US-Dollar | ||
| IOVANCE BIOTHERAPEUTICS | 1,886 | +0,28 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ||
| COHERUS ONCOLOGY | 1,505 | +4,99 % | Coherus Oncology: Nach der Rallye folgt der Durchbruch? | Die Aktie von Coherus Oncology hat in den vergangenen Monaten deutlich an Dynamik gewonnen. Mit über 60 Prozent Kursplus seit April 2025 rückt das Unternehmen ins Rampenlicht - getragen von wachsenden... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,884 | +0,41 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
| GUARDANT HEALTH | 59,40 | -0,54 % | Colon Cancer Screening Leader Guardant Health Tests Buy Point As Earnings Loom | ||
| ESPERION | 2,300 | -0,13 % | ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up | ||
| VOYAGER THERAPEUTICS | 3,990 | +1,73 % | Voyager Therapeutics, Inc.: Voyager Reports Second Quarter 2025 Financial and Operating Results | - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise... ► Artikel lesen |